Clinical trials · Washington, D.C., DC
Ovarian cancer clinical trials in Washington, D.C.
We’re tracking 86 recruiting ovarian cancer studies with a site in or near Washington, D.C. — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT01441089Recruiting
Donate blood for genetic testing in an NIH research study
This study collects blood from people already in an NIH (National Institutes of Health) clinical research program to run genetic tests. It may help researchers understand cancer and related inherited conditions by studying DNA changes.
Bethesda, MarylandAges 3 years+ - NCT05440617Recruiting
Biobank for people having testicle-protecting cancer treatment
This study collects and stores biological samples from people who are planning to undergo OTC, a treatment used to help protect fertility during cancer therapy that can harm reproductive cells. It may help future research by providing researchers with tissue/blood samples linked to this treatment.
Bethesda, MarylandAges 4–35 - NCT03762733Enrolling by invitation
Study of stored breast or gynecologic cancer tissue for DNA testing
This study collects and stores tissue from people with breast cancer or other gynecologic cancers to do DNA (genomics) testing. It may help researchers better understand these cancers by comparing genetic patterns from real patient tissue.
Bethesda, MarylandAges 18 years+ - NCT04847063RecruitingPhase 1
Test drug heating inside the abdomen for peritoneal cancer
This Phase 1 trial tests a treatment that delivers heated chemotherapy directly into the abdomen (HIPEC) for certain cancers that have spread only within the abdominal lining. It aims to see how safely and effectively this approach works, especially when doctors can remove as much tumor as possible.
Bethesda, MarylandAges 18–120 - NCT06885697RecruitingPhase 1
CAR T cells targeting mesothelin for solid tumors
This study tests a new treatment called CAR T cells that target a protein called mesothelin found on certain cancer cells. The CAR T cells are made from your own immune cells and may help shrink tumors that have not responded to other therapies.
Bethesda, MarylandAges 18–120 - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Falls Church, VirginiaAges 18 years+ - NCT06566716Recruiting
Blood test to check for cancer risk before ovarian mass surgery
This study tests a new blood test to help doctors determine if an ovarian mass is cancerous before surgery. If you are a woman over 18 with an ovarian cyst or mass that needs surgery, this test could help guide your care.
Annandale, VirginiaAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Rockville, MarylandAges 18 years+ - NCT05128825RecruitingPhase 2
Test drug azenosertib for platinum-resistant ovarian cancer
This Phase 2 trial tests azenosertib to treat platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. It looks for whether the drug can shrink tumors and improve outcomes in people whose cancer has returned after platinum chemotherapy.
Rockville, MarylandAges 18 years+ - NCT06234423RecruitingPhase 1
A study of CUSP06 for advanced solid tumors
This study tests a new drug called CUSP06 for people with advanced solid tumors, especially ovarian cancer that has stopped responding to platinum chemotherapy. It may help if standard treatments no longer work.
Fairfax, VirginiaAges 18 years+ - NCT07524322RecruitingPhase 1
RGT-490 for Advanced Cancers With PIK3CA Mutations
This study tests a new drug called RGT-490 in patients with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have a specific genetic change called a PIK3CA mutation. The drug is designed to block a protein involved in cancer cell growth.
Fairfax, VirginiaAges 18 years+ - NCT06303505RecruitingPhase 1/Phase 2
Study of TUB-040 for ovarian and lung cancer
This study tests a new drug called TUB-040 that targets a protein (NaPi2b) found on some ovarian and lung cancer cells. It is for people whose cancer has stopped responding to standard treatments and who have not had certain lung problems in the past.
Fairfax, VirginiaAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Fairfax, VirginiaAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Fairfax, VirginiaAges 18 years+ - NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Fairfax, VirginiaAges 18 years+ - NCT07278336RecruitingPhase 1
Study of ABBV901 for ovarian cancer
This trial tests a new drug called ABBV901, given alone or with another drug (bevacizumab), for people with a certain type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if it helps control the disease.
Fairfax, VirginiaAges 18 years+ - NCT05659381RecruitingPhase 3
Heated belly chemo plus niraparib after interval surgery for ovarian cancer
This Phase 3 study tests whether heated chemotherapy placed inside the belly, followed by interval surgery and the maintenance medicine niraparib, can improve outcomes for certain advanced ovarian, fallopian tube, or primary peritoneal cancers. It focuses on people whose tumors are HRD/LOH positive and who can have all visible disease removed.
Fairfax, VirginiaAges 18 years+ - NCT07226427RecruitingPhase 1
Study of MEN2501 for platinum-resistant ovarian cancer
This trial tests a new drug called MEN2501 for people with ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if it is safe and if it can help shrink tumors.
Fairfax, VirginiaAges 18 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
Fairfax, VirginiaAges 18 years+ - NCT06840886RecruitingPhase 1
Testing a new drug for advanced solid tumors
This study tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can help shrink tumors.
Fairfax, VirginiaAges 18 years+ - NCT05746897RecruitingPhase 1
First-in-human test of an anti-PVRIG drug for advanced cancers
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Fairfax, VirginiaAges 18 years+ - NCT06906341RecruitingPhase 2
Relacorilant combo for gynecologic cancers
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
Fairfax, VirginiaAges 18 years+ - NCT05080946RecruitingEarly Phase 1
Aspirin with chemotherapy to improve ovarian tumor immune features
This early-phase study tests whether adding aspirin to standard neoadjuvant chemotherapy can change immune (anti-tumor) features inside ovarian, fallopian tube, or peritoneal tumors. It may help doctors better understand which patients respond and how aspirin could make treatment work better.
Fairfax, VirginiaAges 18 years+
Hear when a new Ovarian cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Ovarian cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting ovarian cancer studies listed above.
- NEXT Oncology · 7 studies
- National Institutes of Health Clinical Center · 5 studies
- Inova Schar Cancer Institute · 4 studies
- Virginia Cancer Specialists · 4 studies
- Maryland Oncology Hematology, P.A. · 2 studies
- 522
- Dren Investigational Site
- Investigative Site #112
What taking part in a ovarian cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there ovarian cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 86 recruiting ovarian cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a ovarian cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New ovarian cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.